Thrombus Formation Under Different Flow-conditions
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Rationale: Cardiovascular diseases are important causes of morbidity and mortality in the industrialized world. Clinical studies indicate an important role for the proteins of the contact activation system (coagulation factor XII (FXII), FXI, prekallikrein and high molecular weight kininogen (HMWK)) on the risk of cardiovascular disease. There is substantial evidence from mouse studies that FXII and FXI participate in the formation and stability of thrombi and in vitro studies showed that collagen is able to activate FXII and hereby stimulate thrombin formation and potentiate the formation of platelet-fibrin thrombi. The investigators want to determine the role of the proteins of the contact activation system in platelet mediated thrombus formation in human blood.
Objective: The investigators will study the effects of the proteins of the contact activation system on platelet mediated thrombus formation, embolization and degradation on collagen in a perfusion flow model.
Study design: Blood will be collected from human volunteers via a venipuncture in the forearm. Each volunteer will donate maximally four times 30 ml of blood over a period of two days. This blood is used in perfusion flow experiments: blood flows over a coverslip covered with collagen in a flow chamber. The investigators will vary several conditions such as the concentration of the proteins and the shear rate. For perfusion flow experiments, the investigators need fresh whole blood because platelets are viable for four hours. After this time, new blood is needed.
Study population: For this study the investigators need blood from human volunteers with a coagulation defect in one of the proteins of the contact activation system, e.g. FXII, FXI, prekallikrein or HMWK and controls without any coagulation defects.
Main study parameters/endpoints: The investigators main study endpoint is the ex vivo formation of platelet-mediated thrombi on collagen in a perfusion flow model. The investigators hypothesize that thrombi formed from blood of patients deficient in FXII or FXI are less stable than those formed from blood from controls.
| Condition |
|---|
|
Thrombosis |
| Study Type: | Observational |
| Study Design: | Time Perspective: Cross-Sectional |
| Official Title: | The Influence of the Proteins of the Contact Activation System on Thrombus Formation Under Different Flow-conditions in Blood |
- Thrombus formation, stability and break down [ Time Frame: Up to 36 months ] [ Designated as safety issue: No ]Using perfusion-flow experiments the formation, stability and break down of clots formed from the blood of the study participants will be determined.
Biospecimen Retention: Samples Without DNA
- Whole blood
- Platelet poor plasma
| Estimated Enrollment: | 46 |
| Study Start Date: | May 2011 |
| Estimated Study Completion Date: | May 2013 |
| Estimated Primary Completion Date: | May 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Factor XII deficiency
Patients deficient in coagulation factor XII
|
|
Factor XI Deficiency
Patients deficient in coagulation factor XI
|
|
Prekallikrein deficiency
Patients deficient in prekallikrein
|
|
HMWK deficiency
Patients deficient in high molecular weight kininogen (HMWK)
|
|
Control group
Healthy controls
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Patients:
Patients with a congenital factor XII-deficiency Patients with a congenital factor XI-deficiency Patients with a congenital prekallikrein-deficiency Patients with a congenital high molecular weight kininogen-deficiency
Controls:
Healthy individuals without any coagulation defects
Inclusion Criteria:
- Patient group:
- Age: ≥ 18 years
- Deficiency in factor XII, factor XI, prekallikrein or high molecular weight kininogen
- Control group:
- Age: ≥ 18 years
Exclusion Criteria:
- (Other) Coagulation defects
- Symptoms of active disease
- The use of antiplatelet drugs
- The use of aspirin/ascal
Contacts and Locations| Contact: Joke Konings, MSc | +31-433881542 | J.Konings@maastrichtuniversity.nl |
| Contact: José WP Govers-Riemslag, PhD | +31-433884263 | J.Govers@maastrichtuniversity.nl |
| Netherlands | |
| Maastricht University | Recruiting |
| Maastricht, Limburg, Netherlands, 6229 ER | |
| Contact: Joke Konings, MSc +31-433881542 J.Konings@BIOCH.unimaas.nl | |
| Contact: José WP Govers-Riemslag, PhD +31-433884263 J.Govers@BIOCH.unimaas.nl | |
| Principal Investigator: Joke Konings, MSc | |
| Principal Investigator: | Hugo Ten Cate, MD, PhD | Maastricht University Medical Centre |
More Information
No publications provided
| Responsible Party: | Maastricht University Medical Center |
| ClinicalTrials.gov Identifier: | NCT01114074 History of Changes |
| Other Study ID Numbers: | 10-3-015, #2008B120 |
| Study First Received: | April 12, 2010 |
| Last Updated: | August 25, 2011 |
| Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
Keywords provided by Maastricht University Medical Center:
|
Thrombosis Blood coagulation Perfusion flow experiments Factor XII |
Factor XI Prekallikrein High molecular weight kininogen |
Additional relevant MeSH terms:
|
Thrombosis Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases |
ClinicalTrials.gov processed this record on June 18, 2013